Jean-Francois Baurain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Francois Baurain has a total of 236 co-authors. Here are the top co-authors by number of shared publications:
- Jessica Cecile Hassel
Department of Dermatology, University Hospital Heidelberg and National Center for Tumor Diseases (NCT), NCT Heidelberg, a Partnership Between DKFZ and University Hospital Heidelberg, 69120 Heidelberg, Germany
23 shared publications - Paul M. Clement
Department of Oncology, Leuven Cancer Institute, KU Leuven, Leuven, Belgium
19 shared publications - Anna K. Nowak
Medical School, University of Western Australia, Perth, Australia
18 shared publications - C. Mircea S. Tesileanu
Department of Neurosurgery, Yale University, New Haven, USA
18 shared publications - Helen Wheeler
13Northern Sydney Cancer Centre, University of Sydney, St Leonards, New South Wales, Australia
18 shared publications - Kenneth Aldape
Department of Laboratory Medicine and Pathobiology, Mayo Clinic , Rochester, Minnesota
18 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 14
Using machine learning to estimate time-to-progression in ovarian cancer based on cancer registry and administrative health data
- 5 October 2026
- Published by Elsevier in ESMO Real World Data and Digital Oncology
- Vol. 14
Open AccessUsing machine learning to estimate time-to-progression in ovarian cancer based on cancer registry and administrative health data
- Open Access
- 19 May 2026
- Published by Elsevier in Annals of Oncology
Five-year survival with tebentafusp in metastatic uveal melanoma
- 19 May 2026
- Published by Elsevier in Annals of Oncology
Open AccessFive-year survival with tebentafusp in metastatic uveal melanoma
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (1)
Adjuvant treatment algorithm based on recent ESGO/ESTRO/ESP guidelines for early endometrial carcinoma according to prognostic risk groups
Baurain JF, et al. J Gynecol Oncol. 2025 Oct;37:e28. https://doi.org/10.3802/jgo.2026.37.e28
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37 (1)
Open AccessAdjuvant treatment algorithm based on recent ESGO/ESTRO/ESP guidelines for early endometrial carcinoma according to prognostic risk groups
Baurain JF, et al. J Gynecol Oncol. 2025 Oct;37:e28. https://doi.org/10.3802/jgo.2026.37.e28
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Landmark OS for corticosteroid use within the first 30 days of the first tebentafusp dose. Kaplan–Meier plot of inverse probability of treatment–weighted OS (ATE weights) by corticosteroid use within the first 30 days of the first tebentafusp dose, landmarked at day 30. HR (95% confidence interval), 1.09 (0.67–1.76). ATE, average treatment effects.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Landmark OS for corticosteroid use within the first 30 days of the first tebentafusp dose. Kaplan–Meier plot of inverse probability of treatment–weighted OS (ATE weights) by corticosteroid use within the first 30 days of the first tebentafusp dose, landmarked at day 30. HR (95% confidence interval), 1.09 (0.67–1.76). ATE, average treatment effects.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Table 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
TRAE occurring in patients with mUM treated with tebentafusp.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
TRAE occurring in patients with mUM treated with tebentafusp.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Table 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Medications used to treat AESI.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 3 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Medications used to treat AESI.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Demographics and baseline characteristics.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Demographics and baseline characteristics.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Attenuation of select TRAE with repeated dosing. Incidence and severity of select TRAE over time for patients with mUM treated with tebentafusp across all studies (N = 410). A, Weekly incidence of TRAE during the acute phase (1–12 weeks). B, Long-term incidence of TRAE in 3-month intervals up to 30 months, which can be broken down into acute (months 1–3), intermediate (months 4–12), and late phases (>12 months). *Rash, LFT, and MRAE are composite terms for a list of related AE of any grade (Supplementary Table S1).
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Attenuation of select TRAE with repeated dosing. Incidence and severity of select TRAE over time for patients with mUM treated with tebentafusp across all studies (N = 410). A, Weekly incidence of TRAE during the acute phase (1–12 weeks). B, Long-term incidence of TRAE in 3-month intervals up to 30 months, which can be broken down into acute (months 1–3), intermediate (months 4–12), and late phases (>12 months). *Rash, LFT, and MRAE are composite terms for a list of related AE of any grade (Supplementary Table S1).
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Frequency of AESI by maximum grade and kinetics of onset and resolution of AESI. A, Frequency of each AESI by grade. CRS was programmatically graded post hoc according to the ASTCT consensus grading criteria for CRS for patients in studies 102 and 202 (N = 391). CTCAE grading for treatment-emergent ASR and elevations in LFT for all patients (N = 410). B and C, Median time to (A) onset from the start of the first dose or (B) resolution from the start of AESI for CRS, ASR, and LFT elevations. The peak of each curve shows the proportion of patients who developed that AESI. CRS was programmatically graded post hoc according to the ASTCT consensus grading criteria for CRS for patients in studies 102 and 202 (N = 391). CTCAE grading for treatment-emergent ASR and elevations in LFT for all patients (N = 410).
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Frequency of AESI by maximum grade and kinetics of onset and resolution of AESI. A, Frequency of each AESI by grade. CRS was programmatically graded post hoc according to the ASTCT consensus grading criteria for CRS for patients in studies 102 and 202 (N = 391). CTCAE grading for treatment-emergent ASR and elevations in LFT for all patients (N = 410). B and C, Median time to (A) onset from the start of the first dose or (B) resolution from the start of AESI for CRS, ASR, and LFT elevations. The peak of each curve shows the proportion of patients who developed that AESI. CRS was programmatically graded post hoc according to the ASTCT consensus grading criteria for CRS for patients in studies 102 and 202 (N = 391). CTCAE grading for treatment-emergent ASR and elevations in LFT for all patients (N = 410).
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Contains all supplementary tables and figures
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Incidence and Management of Adverse Events Associated with Tebentafusp Treatment in Metastatic Uveal Melanoma: Pooled Safety Analysis of 410 Patients
Contains all supplementary tables and figures